Guinness Asset Management’s Thermo Fisher Scientific TMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $41.9M | Sell |
83,662
-9,318
| -10% | -$4.47M | 0.71% | 36 |
|
|
2026
Q1 | $45.7M | Buy |
92,980
+8,049
| +9% | +$4.37M | 0.79% | 31 |
|
|
2025
Q4 | $49.7M | Sell |
84,931
-26
| -0% | -$14.7K | 0.81% | 35 |
|
|
2025
Q3 | $39.3M | Buy |
84,957
+10,925
| +15% | +$5.09M | 0.63% | 39 |
|
|
2025
Q2 | $30M | Sell |
74,032
-1,519
| -2% | -$635K | 0.54% | 39 |
|
|
2025
Q1 | $37.6M | Buy |
75,551
+3,788
| +5% | +$2.05M | 0.72% | 34 |
|
|
2024
Q4 | $37.3M | Buy |
71,763
+12,874
| +22% | +$7.08M | 0.7% | 34 |
|
|
2024
Q3 | $36.4M | Buy |
58,889
+7,763
| +15% | +$4.6M | 0.69% | 32 |
|
|
2024
Q2 | $28.3M | Buy |
51,126
+1,871
| +4% | +$1.07M | 0.58% | 42 |
|
|
2024
Q1 | $28.6M | Buy |
49,255
+4,151
| +9% | +$2.33M | 0.6% | 42 |
|
|
2023
Q4 | $23.9M | Buy |
45,104
+338
| +0.8% | +$164K | 0.52% | 46 |
|
|
2023
Q3 | $22.7M | Buy |
44,766
+2,510
| +6% | +$1.34M | 0.52% | 48 |
|
|
2023
Q2 | $22M | Buy |
42,256
+2,798
| +7% | +$1.51M | 0.51% | 46 |
|
|
2023
Q1 | $22.7M | Buy |
39,458
+45
| +0.1% | +$25.4K | 0.58% | 39 |
|
|
2022
Q4 | $21.7M | Buy |
39,413
+432
| +1% | +$229K | 0.61% | 39 |
|
|
2022
Q3 | $19.8M | Sell |
38,981
-759
| -2% | -$425K | 0.67% | 36 |
|
|
2022
Q2 | $21.6M | Sell |
39,740
-3,497
| -8% | -$1.92M | 0.85% | 31 |
|
|
2022
Q1 | $25.5M | Buy |
43,237
+951
| +2% | +$546K | 0.95% | 36 |
|
|
2021
Q4 | $28.2M | Buy |
42,286
+2,069
| +5% | +$1.29M | 1.1% | 31 |
|
|
2021
Q3 | $23M | Sell |
40,217
-2,253
| -5% | -$1.24M | 1.09% | 33 |
|
|
2021
Q2 | $21.4M | Buy |
42,470
+690
| +2% | +$326K | 1.18% | 41 |
|
|
2021
Q1 | $19.1M | Buy |
41,780
+8,780
| +27% | +$4.19M | 1.2% | 37 |
|
|
2020
Q4 | $15.4M | Buy |
33,000
+5,350
| +19% | +$2.51M | 1.11% | 26 |
|
|
2020
Q3 | $12.2M | Sell |
27,650
-49
| -0.2% | -$20.2K | 1.28% | 22 |
|
|
2020
Q2 | $10M | Sell |
27,699
-1,200
| -4% | -$402K | 1.19% | 23 |
|
|
2020
Q1 | $8.2M | Buy |
28,899
+28,850
| +58,878% | +$9.1M | 1.19% | 22 |
|
|
2019
Q4 | $16K | Hold |
49
| – | – | ﹤0.01% | 98 |
|
|
2019
Q3 | $14K | Sell |
49
-17
| -26% | -$4.87K | ﹤0.01% | 89 |
|
|
2019
Q2 | $19K | Buy |
66
+36
| +120% | +$9.91K | ﹤0.01% | 92 |
|
|
2019
Q1 | $8K | Hold |
30
| – | – | ﹤0.01% | 97 |
|
|
2018
Q4 | $7K | Sell |
30
-11
| -27% | -$2.58K | ﹤0.01% | 98 |
|
|
2018
Q3 | $10K | Hold |
41
| – | – | ﹤0.01% | 86 |
|
|
2018
Q2 | $8K | Hold |
41
| – | – | ﹤0.01% | 90 |
|
|
2018
Q1 | $8K | Hold |
41
| – | – | ﹤0.01% | 91 |
|
|
2017
Q4 | $8K | Hold |
41
| – | – | ﹤0.01% | 90 |
|
|
2017
Q3 | $8K | Hold |
41
| – | – | ﹤0.01% | 89 |
|
|
2017
Q2 | $7K | Hold |
41
| – | – | ﹤0.01% | 93 |
|
|
2017
Q1 | $6K | Hold |
41
| – | – | ﹤0.01% | 93 |
|
|
2016
Q4 | $6K | Buy |
+41
| New | +$6.04K | ﹤0.01% | 98 |
|
Other funds holding TMO
Guinness Asset Management's TMO Position: Q2 2026 in Review
Guinness Asset Management reduced its Thermo Fisher Scientific (TMO) stake by 10% in Q2 2026, selling an estimated $4.47M and leaving 83,662 shares worth $41.9M. The position accounts for 0.71% of the portfolio, ranked #36.
Guinness Asset Management first reported a position in TMO in Q4 2016 and has held it in 39 quarters since. The position peaked at $49.7M in Q4 2025. 2,602 funds tracked by Wall St. Rank hold TMO as of Q2 2026.
- Guinness Asset Management held 83,662 shares of Thermo Fisher Scientific worth $41.9M as of Q2 2026.
- Guinness Asset Management sold 9,318 Thermo Fisher Scientific shares in Q2 2026, an estimated $4.47M.
- Thermo Fisher Scientific made up 0.71% of Guinness Asset Management's portfolio in Q2 2026, its #36 holding.
- Guinness Asset Management first reported a position in Thermo Fisher Scientific in Q4 2016 and has held it in 39 quarters since.
- Guinness Asset Management's Thermo Fisher Scientific position peaked at $49.7M in Q4 2025.
- 2,602 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2026.
Based on Guinness Asset Management's 13F filing for Q2 2026, filed 29 Jul 2026.